Oral Dissolving Strip vs Nasal Spray: Best Use Case

Oral Dissolving Strip vs Nasal Spray: Best Use Case

By Jack Zheng, MS Pharmacy -- Founder of MIHIYO Labs

Summary

An oral dissolving strip (ODS) and a nasal spray both bypass the gut, but they solve different problems. A nasal spray is usually the better route when speed is the top priority: intranasal buprenorphine reached peak plasma levels in 35 to 40 minutes in a human crossover study. An ODS is usually the better route when you want a dry, premeasured dose that is easy to carry and repeat every day, and buccal buprenorphine film reached 46 to 51 percent absolute bioavailability in healthy volunteers. For MIHIYO Labs, that trade-off matters more than hype. Fast is not automatically better if consistency is the real design goal.

Which makes more sense: an oral dissolving strip or a nasal spray?

For most daily supplements, an oral dissolving strip vs nasal spray decision comes down to speed versus repeatability. Nasal sprays are usually the better fit when a rapid effect matters most and the formulation truly works through the nasal mucosa. An ODS is usually the better fit when the real design priority is a dry, unit-dose format that is easy to carry, easy to repeat, and less dependent on device technique.134

That answer needs one honest qualifier. There are very few direct head-to-head human studies that compare a supplement ODS with a matched nasal spray of the same active. So this article rests on route-level reviews and representative human pharmacokinetic studies rather than on one perfect same-molecule showdown. I think that is the defensible way to write this topic: compare what the routes actually do, say where the evidence is strong, and do not pretend there is a cleaner data set than the literature gives us.13

How do the two routes move drug into the bloodstream?

Both routes are attractive because they can bypass ordinary gastrointestinal absorption. Bioavailability is the fraction of a dose that reaches the bloodstream unchanged. If a molecule crosses the nasal or oral mucosa before it is swallowed, part of that dose can avoid the first-pass liver metabolism that makes many swallowed products slower or less efficient.13

The nasal route has one obvious advantage: surface biology built for fast exchange. The nasal cavity is highly vascularized, and intranasal delivery has been studied for systemic drugs specifically because it can provide rapid absorption without an injection.3 That is why the route shows up so often in emergency or rescue settings. The trade-off is that the same nasal cavity is also a clearance system. Mucus and cilia are designed to move material toward the nasopharynx, which shortens contact time and makes formulation details matter more than the marketing copy usually admits.2

An oral dissolving strip works differently. The film hydrates in saliva, adheres to the oral mucosa, and releases a fixed dose from a polymer matrix. Oral thin films were developed partly because a dry film is easier to self-administer than many conventional dosage forms, especially for people who do not want to swallow tablets or need water nearby.4 The route is usually less dramatic than the best intranasal rescue formulations, but it is often more controlled because the dose is premeasured and the administration step is simpler.

Mucociliary clearance is the technical term for the nose's self-cleaning system. That system is useful for airway defense, but it is also one of the main reasons intranasal absorption can be formulation-sensitive.2 By contrast, the oral film problem is usually dose loading and mucosal permeability. Not every ingredient is suitable for an ODS, and not every useful intranasal drug belongs in a supplement format.14

How a nasal spray and an oral dissolving strip reach the bloodstream by different routes A nasal spray offers a faster absorption opportunity but faces mucus clearance and nasal-environment variability, while an oral dissolving strip adheres and releases a fixed dose more steadily for daily use. Nasal spray Oral dissolving strip Sprayed into nose Plume placement matters Mucus and cilia Clearance can shorten contact time Rapid absorption chance Strong fit when speed matters most Placed on oral mucosa Dry unit dose, no device plume Film hydrates and adheres Release is slower but more controlled Repeatable daily dosing Strong fit for travel and nightly use Both can bypass the gut Nasal spray usually wins on urgency; oral dissolving strip usually wins on repeatable daily fit.

What do the human studies show about speed, consistency, and practicality?

The evidence is easiest to understand when the routes are broken into concrete decisions rather than broad claims.

Dimension Nasal spray Oral dissolving strip (ODS) Source
Onset opportunity Often faster when the route is optimized for urgent systemic delivery Usually fast relative to tablets, but often built more for controlled daily use than emergency speed Debe et al., 2025; Middleton et al., 2011; Sallam et al., 2017168
Representative PK number Intranasal buprenorphine bioavailability 38-44%, Tmax 35-40 min Buccal buprenorphine film absolute bioavailability 46-51%, peak at 2.5-3 h Middleton et al., 2011; Bai et al., 201656
Oral-film example versus tablets Not applicable Terbutaline film showed 204.08% relative bioavailability versus oral tablets; salbutamol film Tmax 0.75 h versus 2.1 h tablet Sayed et al., 2013; Sallam et al., 201778
Physiology sensitivity Nasal anatomy, mucus clearance, and formulation design matter; congestion effects are drug-specific, not uniformly negative Placement and saliva still matter, but the dose itself is fixed and dry Merkus et al., 1998; Blaiss et al., 2025; Sevinc Ozakar and Ozakar, 2021249
Practical fit Strong route for rescue use and needle-free speed Strong route for repeat daily dosing, travel, and users who prefer a single dry unit Debe et al., 2025; Fortuna et al., 2014; Sevinc Ozakar and Ozakar, 2021134
Representative human pharmacokinetic numbers for nasal and oral film delivery Intranasal buprenorphine shows a faster peak time, while oral films show strong systemic exposure and clear improvement over swallowed tablets in representative human studies. Representative human PK examples Intranasal buprenorphine Tmax 35-40 min Bioavailability 38-44% Shows why nasal route stays attractive for rapid use Buccal buprenorphine film Peak 2.5-3 h Bioavailability 46-51% Shows strong systemic exposure from a dry film Salbutamol sublingual film Tmax 0.75 h Comparator tablet Tmax 2.1 h Oral film can beat swallowed tablets on timing Terbutaline sublingual film Relative bioavailability 204.08% Versus conventional oral tablet Best read as a tablet comparison, not a nasal claim These numbers come from different molecules and studies, so they illustrate route fit rather than a single direct head-to-head winner.

The speed argument for nasal delivery is real. In the buprenorphine misuse study, intranasal buprenorphine reached peak plasma levels in 35 to 40 minutes with bioavailability of 38 to 44 percent.6 That does not mean every nasal spray will behave the same way, but it does show why the route stays attractive when minutes matter. The 2025 Journal of Pharmaceutical Sciences review makes the broader point clearly: both nasal and sublingual routes can support emergency drug delivery, but nasal products are often favored when immediate onset is the central design goal.1

The ODS argument is different. The buccal buprenorphine film study found absolute bioavailability of 46 to 51 percent across a 16-fold dose range, with dose-proportional exposure.5 That is not a claim that oral films are always more bioavailable than nasal sprays. It is a claim that a well-designed transmucosal film can deliver meaningful, reproducible systemic exposure from a premeasured dry unit. The salbutamol and terbutaline studies reinforce the same point from a supplement-adjacent angle: sublingual films can outperform swallowed tablets on speed or exposure when first-pass metabolism is the bottleneck.78

The physiology question is where the comparison gets more nuanced. The common shorthand is that congestion makes nasal delivery unreliable. The newest rescue-medication review does not support that as a universal rule. Blaiss and colleagues found no negative effect of congestion across several intranasal rescue-drug studies, and some epinephrine formulations even showed higher peak concentrations under induced congestion.9 That is useful because it stops the article from making a lazy claim. Congestion does not automatically break the route. It tells us something more precise: nasal performance depends on the individual drug, the formulation, and the state of the nasal cavity.39

That still leaves a practical difference. Nasal sprays are device-mediated. They depend on spray plume, placement, nasal comfort, and a tissue environment that varies with allergy, illness, and dryness.23 An ODS depends on the permeability of the oral mucosa too, but the administration step is simpler: place the film, let it hydrate, and wait for it to dissolve. For a nightly or daily supplement, that reduction in user-step variability matters more to me than shaving a few minutes off the fastest possible onset.

What this means for MIHIYO products

For a product like Sleep-Support, I think the ODS format is the better design choice. The use case is repeated daily dosing, not emergency rescue. In that setting I care more about a stable unit dose, dry packaging, and a format people can use without water than I do about turning the product into a nasal-delivery exercise.4 That is also why the related articles on melatonin strip dosage and onset time keep coming back to route logic instead of hype.

I also would not overclaim the nasal route just because it sounds more clinical. Nasal delivery has real strengths, and I would take it seriously for drugs or situations where immediate onset dominates every other consideration.13 But most supplements are not rescue products. They are daily products, often used at home, in travel, or before sleep. In that context, an oral film's simplicity is not a small convenience detail. It is part of the pharmacologic design, because a format that is easier to repeat correctly is often the more honest format.

There is a second boundary I want to keep explicit. None of the cited studies here were run on a finished MIHIYO retail product, and there is no published head-to-head trial of a MIHIYO strip versus a matched nasal spray. The citations support route decisions and formulation philosophy, not a claim that MIHIYO has already outperformed a nasal comparator in a direct human trial.156

If a reader already knows and likes nasal sprays, I would frame the difference this way: the best reason to choose a spray is urgency; the best reason to choose an ODS is repeatable daily fit. That is a cleaner and more honest distinction than pretending one route simply wins every time.

Where each approach falls short

Nasal sprays are not magic. Dose volume is limited, local comfort can be an issue, and the formulation has to survive a route that is built to clear foreign material.23 Even when congestion does not reduce absorption, the route still lives inside a variable tissue environment that changes with season, illness, and device technique.9

An ODS has its own ceilings. Thin films cannot carry every dose size gracefully, and some actives simply do not permeate the oral mucosa well enough to justify the format.4 Very dry mouth can also make film hydration slower or less comfortable. And if the question is pure emergency speed, the best intranasal products will usually be the harder route to beat.1

That is why I do not think this comparison should end with a winner-take-all line. A good dosage form is a fit decision. The route needs to match the active, the dose, the timing goal, and the user's real behavior. In formulation work, the most elegant route on paper is often less important than the route a person can actually use correctly every time.

The bottom line

An oral dissolving strip vs nasal spray comparison is really a comparison of priorities. If the priority is the fastest plausible needle-free onset, nasal spray usually has the edge.16 If the priority is a dry, fixed, easy-to-repeat daily dose, the oral dissolving strip is usually the better tool.45 For MIHIYO Labs, that is the more relevant design standard. Fast matters, but consistency matters more for a supplement people use again tomorrow.

References

  1. Debe MS, Khan SA, Ahmed IS, Hussain Z, Uddin MN, Rawas-Qalaji M. Nasal versus sublingual routes for emergency drug administration. J Pharm Sci. 2025. PMID: 40639458 / DOI: 10.1016/j.xphs.2025.103903. <https://pubmed.ncbi.nlm.nih.gov/40639458/>
  2. Merkus FWHM, Verhoef JC, Schipper NGM, Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1-2):13-38. PMID: 10837578 / DOI: 10.1016/S0169-409X(97)00059-8. <https://pubmed.ncbi.nlm.nih.gov/10837578/>
  3. Fortuna A, Alves G, Serralheiro A, Sousa J, Falcao A. Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules. Eur J Pharm Biopharm. 2014;88(1):8-27. PMID: 24681294 / DOI: 10.1016/j.ejpb.2014.03.004. <https://pubmed.ncbi.nlm.nih.gov/24681294/>
  4. Sevinc Ozakar R, Ozakar E. Current Overview of Oral Thin Films. Turk J Pharm Sci. 2021;18(1):111-121. PMID: 33634686 / DOI: 10.4274/tjps.galenos.2020.76390. <https://pubmed.ncbi.nlm.nih.gov/33634686/>
  5. Bai SA, Xiang Q, Finn A. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. Clin Ther. 2016;38(2):358-369. PMID: 26804639 / DOI: 10.1016/j.clinthera.2015.12.016. <https://pubmed.ncbi.nlm.nih.gov/26804639/>
  6. Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106(8):1460-1473. PMID: 21395892 / DOI: 10.1111/j.1360-0443.2011.03424.x. <https://pubmed.ncbi.nlm.nih.gov/21395892/>
  7. Sayed S, Ibrahim HK, Mohamed MI, El-Milligi MF. Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation. Mol Pharm. 2013;10(8):2942-2947. PMID: 23883311 / DOI: 10.1021/mp4000713. <https://pubmed.ncbi.nlm.nih.gov/23883311/>
  8. Sallam NM, Sanad RA, Kharshoom RM, Zeneldin MA. Development of Salbutamol Sulphate Sublingual Films in Pullulan Matrix for Enhanced Bioavailability & Clinical Efficacy. Curr Drug Deliv. 2017;14(3):390-397. PMID: 27784211 / DOI: 10.2174/1567201813666161024161308. <https://pubmed.ncbi.nlm.nih.gov/27784211/>
  9. Blaiss M, Wallace D, Han JK, Rance K. Impact of nasal congestion on intranasal rescue medication absorption and efficacy: A systematic review. Allergy Asthma Proc. 2025;46(4):282-291. PMID: 40958189 / DOI: 10.2500/aap.2025.46.250061. <https://pubmed.ncbi.nlm.nih.gov/40958189/>

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.